Yongping X. Chen

Zhejiang Provincial Key Laboratory For Accurate Diagnosis And Treatment Of Chronic Liver Diseases
Wenzhou, 325000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Retraction notice to "the molecular structure of SHISA5 protein and its novel role in primary biliary cholangitis: From single-cell RNA sequencing to biomarkers" [Int. J. Biol. Macromol. 296 (2025) 139775].

Retraction notice to "the molecular structure of SHISA5 protein and its novel role in primary biliary cholangitis: From single-cell RNA sequencing to biomarkers" [Int. J. Biol. Macromol. 296 (2025) 139775].

Journal: International journal of biological macromolecules

Published: August 21, 2026

AKR1B15 promotes hepatocarcinogenesis by activating the p53-PI3K-AKT-mTOR-E2F1 signaling pathway.

AKR1B15 promotes hepatocarcinogenesis by activating the p53-PI3K-AKT-mTOR-E2F1 signaling pathway.

Journal: Scientific reports

Published: May 26, 2026

Machine learning and radiomics-based model for predicting response to lenvatinib combined with TACE in patients with unresectable hepatocellular carcinoma

Machine learning and radiomics-based model for predicting response to lenvatinib combined with TACE in patients with unresectable hepatocellular carcinoma

Journal: Zhonghua yi xue za zhi

Published: March 30, 2026

Friedelin and 6-methoxyflavone from Imperata cylindrica ameliorate APAP-induced liver injury by activating AKT1 to suppress Caspase-3/GSDME-mediated pyroptosis.

Friedelin and 6-methoxyflavone from Imperata cylindrica ameliorate APAP-induced liver injury by activating AKT1 to suppress Caspase-3/GSDME-mediated pyroptosis.

Journal: European journal of pharmacology

Published: January 29, 2026

Osthole targets doublecortin like kinase 1 (DCLK1/DCAMKL1) in macrophages to inhibit NF-κB-mediated inflammation and alleviate atherosclerosis.

Osthole targets doublecortin like kinase 1 (DCLK1/DCAMKL1) in macrophages to inhibit NF-κB-mediated inflammation and alleviate atherosclerosis.

Journal: British journal of pharmacology

Published: January 19, 2026

Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.

Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.

Journal: Hepatology international

Published: January 04, 2026

Ishak stage 6 fibrosis is more likely to regress than stage 5 in CHB patients undergoing entecavir therapy.

Ishak stage 6 fibrosis is more likely to regress than stage 5 in CHB patients undergoing entecavir therapy.

Journal: Frontiers in medicine

Published: December 11, 2025

Single cell sequencing technology for analyzing the interaction between type 3 innate lymphoid cells and regulatory T cells in patients with fibrostenotic Crohn's disease

Single cell sequencing technology for analyzing the interaction between type 3 innate lymphoid cells and regulatory T cells in patients with fibrostenotic Crohn's disease

Journal: Zhonghua yi xue za zhi

Published: November 19, 2025

Perfluorooctane sulfonates drives colitis via a gut microbiota-bile acid-endoplasmic reticulum stress axis in mice: Mechanistic validation and targeted interventions.

Perfluorooctane sulfonates drives colitis via a gut microbiota-bile acid-endoplasmic reticulum stress axis in mice: Mechanistic validation and targeted interventions.

Journal: Journal of hazardous materials

Published: October 09, 2025

The mechanism of CISD3 regulating NRF2-ATP7B to ameliorate alcohol-induced liver mitochondrial dysfunction and cuproptosis.

The mechanism of CISD3 regulating NRF2-ATP7B to ameliorate alcohol-induced liver mitochondrial dysfunction and cuproptosis.

Journal: International immunopharmacology

Published: August 24, 2025

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial.

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial.

Journal: Hepatology international

Published: August 19, 2025

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.

Journal: European journal of medical research

Published: May 06, 2025

Showing 1-12 of 80

Last Updated: 09/26/2026